Peritoneal Metastases
1Peritoneal Carcinomatosis Center, NPO Organization to support Peritoneal Surface Malignancy Treatment, Japan; Kishiwada Tokushukai Hospital, Osaka, Japan; Kusatsu General Hospital, Shiga, Japan; Ikeda Hospital, Shizuoka, Japan
2Department of Oncology, Zhongnan Hospital of Wuhan University, No 169, Donghu Road, Wuchang District, Wuhan 430071, China
3Program in Peritoneal Surface Malignancy, Washington Hospital Center, 106 Irving Street, NW, P.O. Box 3900, Washington, DC 20010, USA
4St. John of God Hospital and University of Regensburg, Ratisbon, Germany
Peritoneal Metastases
Description
The current state-of-the-art treatment for peritoneal carcinomatosis consists of a comprehensive management strategy using cytoreductive surgery and perioperative intraperitoneal/systemic chemotherapy. A paradigm shift occurred after the introduction of the treatment, and now the peritoneal carcinomatosis is the disease which can be cured.
In this special issue, we particularly take an interest in manuscripts that deal with any aspects of peritoneal metastases. Potential topics include, but are not limited to:
- The mechanisms of the formation of peritoneal carcinomatosis
- Diagnosis of PC
- Pharmacokinetics of perioperative chemotherapy
- Surgical techniques of peritonectomy
- Perioperative chemotherapy
- Morbidity, mortality, and postoperative care
- Indication of the strategy
- Long-term results and treatment failure
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/grp/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: